Market: NYQ |
Currency: USD
Address: One Manhattan West
W. P. Carey ranks among the largest net lease REITs with a well-diversified portfolio of high-quality, operationally critical commercial real estate, which includes 1,424 net lease properties covering approximately 173 million square feet and a portfolio of 89 self-storage operating properties as of December 31, 2023. With offices in New York, London, Amsterdam and Dallas, the company remains focused on investing primarily in single-tenant, industrial, warehouse and retail properties located in the U.S. and Northern and Western Europe, under long-term net leases with built-in rent escalations.
📈 W. P. Carey Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$70.27
-
Upside/Downside from Analyst Target:
1.30%
-
Broker Call:
3
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
2026-04-29
-
EPS Estimate:
0.62
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for W. P. Carey Inc.
| Date | Reported EPS |
|---|
| 2026-04-28 (estimated upcoming) | - |
| 2026-02-10 | 0.66 |
| 2025-10-28 | 0.67 |
| 2025-07-29 | 0.8 |
| 2025-04-29 | 0.59 |
| 2025-02-11 | 0.6 |
| 2024-10-29 | 0.56 |
| 2024-07-30 | 0.54 |
| 2024-04-30 | 0.72 |
| 2024-02-09 | 0.66 |
| 2023-11-03 | 0.58 |
| 2023-07-28 | 0.67 |
| 2023-04-28 | 1.39 |
| 2023-02-10 | 1 |
| 2022-11-04 | 0.51 |
| 2022-07-29 | 0.66 |
| 2022-04-29 | 0.67 |
| 2022-02-11 | 0.66 |
| 2021-10-29 | 0.57 |
| 2021-07-30 | 0.53 |
| 2021-04-30 | 0.47 |
| 2021-02-12 | 0.44 |
| 2020-10-30 | 0.49 |
| 2020-07-31 | 0.61 |
| 2020-05-01 | 0.49 |
📰 Related News & Research
-
Marubi Biotechnology 2026 Outlook: Revenue Growth, New Products & Investment Risks Explained
April 6, 2026
Broker: China Galaxy International Securities Date of Report...
-
Merit Medical Acquires View Point Medical to Expand Breast and Soft Tissue Tumor Localization Portfolio
April 2, 2026
Merit Medical Systems Acquires View Point Medical: Detailed ...
-
Atlas Energy Solutions Secures 5-Year 120MW Power Purchase Agreement and Raises 2026 Financial Guidance
April 1, 2026
Atlas Energy Solutions Announces Major Power Purchase Agreem...
-
Inhibitor Therapeutics Advances Amorphous Itraconazole Formulation for Gorlin Syndrome With New Patent Filing and Clinical Milestones 12
April 1, 2026
Inhibitor Therapeutics Provides Key Update on Itraconazole P...
-
New Providence Acquisition Corp. III 2025 Annual Report: Business Combination Strategy, Risks, and Management Overview
April 1, 2026
New Providence Acquisition Corp. III 2025 Annual Report: Key...
-
Soluna Holdings Reports Record 2025 Growth: $142M Raised, 4.3GW Pipeline, & AI Infrastructure Launch
March 30, 2026
Soluna Holdings, Inc. Reports Record 2025 Growth, Expands AI...
-
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS
March 24, 2026
Amylyx Pharmaceuticals: Key Pipeline Updates, Clinical Miles...
-
MiNK Therapeutics Appoints New Principal Financial Officer – SEC 8-K Filing Details and Company Information
March 20, 2026
MiNK Therapeutics, Inc. Announces Appointment of New Princip...
-
Battalion Oil Closes All-Stock Acquisition of Sundown Assets, Expanding Monument Draw Position by 7,090 Acres
March 20, 2026
Battalion Oil Corporation Closes Sundown Assets Acquisition,...
-
Hongcheng Environmental Technology Expects 48% Profit Increase for 2025 Driven by Higher Product Prices and New Product Launches
March 19, 2026
Hongcheng Environmental Technology Issues Positive Profit Al...
🔍 View more Reports